Pharmaceutical Companies

PaxMedica, Inc.

Country: 🇺🇸United States

Ownership: Public

Established: 2018-01-01

Employees: 7

Market Cap: $1.7M

Website: http://www.paxmedica.com

PaxMedica, Inc.

🇺🇸United States

Ownership: Public

Established: 2018-01-01

Employees: 7

Market Cap: $1.7M

Website: http://www.paxmedica.com

Aslan Pharmaceuticals

Country: 🇸🇬Singapore

Ownership: -

Established: -

Employees: 35

Market Cap: $1.6M

Website: -

ASLAN Pharmaceuticals Ltd is a clinical-stage immunology-focused biopharmaceutical company developing innovative treatments to transform the lives of patients. The company is evaluating ASLAN004, a potential first-in-class antibody targeting the IL-13 receptor, in atopic dermatitis, and ASLAN003, a potent oral inhibitor of DHODH, which is being developed for autoimmune disease. The Company’s major business is researc...

Aslan Pharmaceuticals

🇸🇬Singapore

Ownership: -

Established: -

Employees: 35

Market Cap: $1.6M

Website: -

Evofem Biosciences, Inc.

Country: 🇺🇸United States

Ownership: Public

Established: 2009-01-01

Employees: 51

Market Cap: $1M

Website: http://www.evofem.com

Evofem Biosciences, Inc.

🇺🇸United States

Ownership: Public

Established: 2009-01-01

Employees: 51

Market Cap: $1M

Website: http://www.evofem.com

Lucy Scientific Discovery Inc

Country: 🇨🇦Canada

Ownership: -

Established: -

Employees: -

Market Cap: $906.9K

Website: -

Lucy Scientific Discovery Inc

🇨🇦Canada

Ownership: -

Established: -

Employees: -

Market Cap: $906.9K

Website: -

Advaxis, Inc.

Country: 🇺🇸United States

Ownership: Public, Subsidiary

Established: 2002-01-01

Employees: 51

Market Cap: $851.8K

Website: http://www.advaxis.com

Advaxis, Inc.

🇺🇸United States

Ownership: Public, Subsidiary

Established: 2002-01-01

Employees: 51

Market Cap: $851.8K

Website: http://www.advaxis.com

Cadrenal Therapeutics

Country: 🇺🇸United States

Ownership: Public

Established: 2022-01-01

Employees: 4

Market Cap: $429.1K

Website: http://www.cadrenal.com

Cadrenal Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which focused on developing novel therapy. It develops tecarfarin, a novel therapy with orphan drug indication, designed for the prevention of systemic thromboembolism of cardiac origin in patients with end-stage renal disease and atrial fibrillation. The company was founded by Quang Pham and Matthew Szot on January 25, 2022 and is headquarter...